ECHS1: A Potential Drug Target and Biomarker (G1892)

Target Name: ECHS1

NCBI ID: G1892

ECHS1

ECHS1: A Potential Drug Target and Biomarker

ECHS1 (endonuclease-associated protein 1) is a protein that is expressed in various tissues and cells in the human body. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential drug targets of ECHS1.

ECHS1 Structure and Function

ECHS1 is a 120-kDa protein that is expressed in various tissues and cells in the human body. It is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain is responsible for the protein's cytoplasmic localization, while the C-terminal domain is involved in the protein's interaction with other cellular components.

ECHS1 plays a role in the regulation of DNA double-strand break repair, a critical process that helps to maintain the integrity of DNA in the cell. It is a key enzyme in the non-homologous endonuclease 1 (NHEJ) family, which is involved in the repair of double-strand breaks in DNA.

ECHS1 has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of ECHS1 are associated with poor prognosis in patients with colorectal cancer. Additionally, ECHS1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

ECHS1 has also been shown to be involved in the regulation of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that ECHS1 is involved in the regulation of T cell function and that it plays a role in the development of autoimmune disorders.

Drug Targets and Biomarkers

ECHS1 has several potential drug targets due to its involvement in the regulation of DNA double-strand break repair and its association with the development of several diseases. One potential drug target for ECHS1 is the inhibition of DNA double-strand break repair, which could lead to the accumulation of genetic mutations that can lead to the development of cancer.

Another potential drug target for ECHS1 is the inhibition of its activity in the NHEJ pathway, which is involved in the repair of double-strand breaks in DNA. This could lead to the accumulation of double-strand breaks that can lead to the development of neurodegenerative diseases.

ECHS1 has also been shown to be involved in the regulation of T cell function, which is a critical part of the immune system. This suggests that ECHS1 may be a potential biomarker for the development of autoimmune disorders.

ECHS1 has been shown to be expressed in various tissues and cells in the human body, including the brain, spinal cord, and peripheral tissues. This suggests that it may be a potential drug target for the treatment of neurodegenerative diseases.

Conclusion

ECHS1 is a protein that is involved in the regulation of DNA double-strand break repair and has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential drug targets and biomarkers make it an attractive target for future research and development. Further studies are needed to fully understand the biology and potential drug targets of ECHS1.

Protein Name: Enoyl-CoA Hydratase, Short Chain 1

Functions: Converts unsaturated trans-2-enoyl-CoA species ((2E)-enoyl-CoA) to the corresponding (3S)-3hydroxyacyl-CoA species through addition of a water molecule to the double bond (PubMed:25125611, PubMed:26251176). Catalyzes the hydration of medium- and short-chained fatty enoyl-CoA thioesters from 4 carbons long (C4) up to C16 (PubMed:26251176). Has high substrate specificity for crotonyl-CoA ((2E)-butenoyl-CoA) and moderate specificity for acryloyl-CoA, 3-methylcrotonyl-CoA (3-methyl-(2E)-butenoyl-CoA) and methacrylyl-CoA ((2E)-2-methylpropenoyl-CoA) (PubMed:26251176). Can bind tiglyl-CoA (2-methylcrotonoyl-CoA), but hydrates only a small amount of this substrate (PubMed:26251176). Plays a key role in the beta-oxidation spiral of short- and medium-chain fatty acid oxidation (PubMed:25125611, PubMed:26251176). At a lower rate than the hydratase reaction, catalyzes the isomerase reaction of trans-3-enoyl-CoA species (such as (3E)-hexenoyl-CoA) to trans-2-enoyl-CoA species (such as (2E)-hexenoyl-CoA), which are subsequently hydrated to 3(S)-3-hydroxyacyl-CoA species (such as (3S)-hydroxyhexanoyl-CoA) (By similarity)

The "ECHS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECHS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets